Prosight Management LP Increases Stake in Humana Inc. (NYSE:HUM)

Prosight Management LP raised its holdings in shares of Humana Inc. (NYSE:HUM – Free Report) by 129.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 55,100 shares of the insurance provider’s stock after acquiring an additional 31,100 shares during the period. Humana makes up 7.6% of Prosight Management LP’s holdings, making the stock its 2nd largest position. Prosight Management LP’s holdings in Humana were worth $24,637,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Silvercrest Asset Management Group LLC boosted its stake in Humana by 3.9% during the 2nd quarter. Silvercrest Asset Management Group LLC now owns 248,784 shares of the insurance provider’s stock worth $111,239,000 after acquiring an additional 9,416 shares during the last quarter. Cerity Partners LLC boosted its position in shares of Humana by 211.1% during the second quarter. Cerity Partners LLC now owns 14,256 shares of the insurance provider’s stock worth $6,375,000 after purchasing an additional 9,674 shares in the last quarter. Glenview Trust Co grew its holdings in shares of Humana by 48.5% in the 2nd quarter. Glenview Trust Co now owns 51,125 shares of the insurance provider’s stock valued at $22,860,000 after buying an additional 16,693 shares during the period. Fund Management at Engine No. 1 LLC increased its position in shares of Humana by 7.3% in the 2nd quarter. Fund Management at Engine No. 1 LLC now owns 1,626 shares of the insurance provider’s stock valued at $727,000 after buying an additional 111 shares in the last quarter. Finally, Eqis Capital Management Inc. raised its stake in Humana by 15.2% during the 2nd quarter. Eqis Capital Management Inc. now owns 1,023 shares of the insurance provider’s stock worth $458,000 after buying an additional 135 shares during the period. Institutional investors and hedge funds own 91.86% of the company’s stock.

Humana Stock Performance

HUM stock traded up $10.35 during trading hours on Friday, reaching $495.21. The stock had a trading volume of 2,178,657 shares, compared to its average volume of 1,334,576. The stock has a 50-day simple moving average of $502.41 and a 200 day simple moving average of $483.87. Humana Inc. has a fifty-two week low of $423.29 and a fifty-two week high of $553.69. The stock has a market capitalization of $60.97 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 1.30 and a beta of 0.55. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.37 and a quick ratio of 1.37.

Humana (NYSE:HUM – Get Free Report) last issued its earnings results on Wednesday, November 1st. The insurance provider reported $7.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.15 by $0.63. The business had revenue of $26.42 billion during the quarter, compared to the consensus estimate of $25.57 billion. Humana had a net margin of 2.95% and a return on equity of 21.03%. Humana’s revenue was up 15.9% on a year-over-year basis. During the same period last year, the business posted $6.88 EPS. Analysts predict that Humana Inc. will post 28.28 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend is Thursday, December 28th. Humana’s dividend payout ratio (DPR) is presently 14.68%.

Analyst Ratings Changes

Several brokerages have issued reports on HUM. Cantor Fitzgerald restated an “overweight” rating and issued a $597.00 price target on shares of Humana in a report on Tuesday, November 21st. Morgan Stanley cut their price target on shares of Humana from $637.00 to $624.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 30th. Sanford C. Bernstein lowered their price objective on shares of Humana from $599.00 to $579.00 in a research report on Tuesday, October 10th. TD Cowen cut their price objective on shares of Humana from $616.00 to $613.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 15th. Finally, JPMorgan Chase & Co. lowered their target price on Humana from $593.00 to $575.00 and set a “neutral” rating for the company in a report on Friday, November 17th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $590.28.

Read Our Latest Analysis on Humana

Humana Company Profile (Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

You may also like

Block Asset Management helping investors back crypto through its fund of

McDonald’s increases minority stake in China business

Sam Altman to Join Microsoft Following OpenAI Ouster